help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-2045
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/3/1651    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cakir, E.
Right arrow Articles by Yesilova, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cakir, E.
Right arrow Articles by Yesilova, Z.
Related Collections
Right arrow Male Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 3 1651-1654
Copyright © 2005 by The Endocrine Society

Elevated Plasma Concentration of Asymmetric Dimethylarginine That Is Reduced by Single Dose Testosterone Administration in Idiopathic Hypogonadotropic Hypogonadism Patients

Erdinc Cakir, Omer Ozcan, Halil Yaman, Emin Ozgur Akgul, Cumhur Bilgi, M. Kemal Erbil and Zeki Yesilova

Departments of Emergency Medicine (E.C., O.O., C.B.), Biochemistry (H.Y., E.O.A., M.K.E.), and Gastroenterology (Z.Y.), Gulhane Military Medical School, Ankara, Turkey

Address all correspondence and requests for reprints to: Dr. Erdinc Cakir, Department of Emergency Medicine, Gulhane Military Medical School, 06010, Etlik, Ankara, Turkey. E-mail: erdcakir{at}yahoo.com.


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Our aim was to investigate whether plasma L-arginine and asymmetric dimethylarginine (ADMA) concentrations and nitric oxide (NO) production are altered in male idiopathic hypogonadotropic hypogonadism (IHH) patients in the hypogonadal state and after single dose testosterone administration compared with those in control subjects. Eighteen newly diagnosed male patients with IHH and 20 healthy volunteer controls matched by age and body mass index were enrolled in the study. Single dose testosterone was administrated im. Initially, pretreatment blood samples were collected after overnight fasting. Posttreatment blood samples were drawn 10 d after the injection. ADMA, L-arginine, and NO were measured in pre- and posttreatment blood samples. The pretreatment ADMA and L-arginine levels were significantly higher, and plasma nitrite plus nitrate (NOx) levels were lower than those in the control group. After 10 d of treatment, ADMA and L-arginine levels were significantly reduced, and NOx levels were significantly increased. There was a significant positive correlation (P < 0.01) between ADMA and L-arginine and a negative correlation between ADMA and NOx levels in patients and controls. In conclusion, the patients with IHH showed elevated plasma ADMA levels associated with a reduction in NO production. Single dose parenteral T administration lowered ADMA concentrations and increased NO production to the control group values.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
TESTOSTERONE (T) SUBSTITUTION in hypogonadal men receives wide recognition, and the number of men being treated with T is constantly increasing (1). Especially in these patients, the role of androgens in vascular functions deserves additional evaluation. The effects of endogenous and, in the substituted patients, exogenous T on atherosclerosis and the development of cardiovascular disease have not been fully resolved, probably due to multiple pathways of an adverse or beneficial nature; T lowers visceral body fat mass and insulin resistance (2, 3) and exerts favorable influence on factors involved in hemostasis (4, 5). Simultaneously, T levels, at least with regard to exogenous T, are negatively associated with high density lipoprotein cholesterol levels and are positively associated with total homocysteine (tHcy) levels, which is considered adverse (6, 7, 8, 9).

Arterial functions, which are modulated by the endothelial cell layer, may also be subject to androgenic influence (10). Endothelial dysfunction is an early event in atherogenesis, appears to have detrimental functional consequences as well as adverse long-term effects, including vascular remodeling, and seems to predict adverse coronary outcomes; thus, gender differences in endothelial function and the effects of hormonal therapy on vascular function have been the focus of considerable research interest (11, 12, 13, 14). T also causes coronary, mesenteric, renal, and iliac vasodilatation in anesthetized animals, the mechanism of which was reported to involve nitric oxide (NO) release and ATP-sensitive K+ channels (15, 16).

NO, synthesized from L-arginine, accounts for the powerful vasodilator effects of endothelium-derived relaxing factor (17, 18) and consequently plays a decisive role in determining vasomotor tone (19, 20). Asymmetric NG,NG-dimethyl-L-arginine (ADMA), a guanidino-substituted analog of L-arginine, is synthesized endogenously and can act as inhibitor of NO synthase (21), the enzyme responsible for the formation of NO from L-arginine. The closely related compound symmetric NG,NG’-dimethyl-L-arginine, a stereoisomer of ADMA, has no inhibitory effect on NO synthase. The plasma levels of these L-arginine analogs are significantly increased in various pathological conditions, including end-stage chronic renal failure (22), congestive heart failure, preeclampsia, peripheral arterial occlusive disease, and hypertension (23, 24).

The purpose of the present study was to evaluate the effect of single dose depot testosterone on plasma L-arginine and dimethylarginine concentrations and their relationship to NO production, measured as plasma nitrite-plus-nitrate (NOx) concentration, in patients with idiopathic hypogonadotropic hypogonadism (IHH), compared with control subjects.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Patients

Eighteen newly diagnosed men with IHH and 20 healthy males matched for age and body mass index were enrolled in the study. The diagnosis of IHH was based on failure to undergo spontaneous puberty before 18 yr of age and was confirmed by decreased serum T concentrations below the normal range for adults, FSH and LH levels within or below the normal range, absence of a pituitary or hypothalamic mass lesion on computed tomography or magnetic resonance imaging, presence of a gonadotropin response to repetitive doses of GnRH, normal smell test, and normal karyotypes (46,XY).

None of the patients had hyposomia, anosomia, or a family history of IHH. All patients had scrotal testes. All controls had normal gonadal development, and their physical and biochemical findings were normal. Patients and controls with a history of hormone replacement therapy; diabetes mellitus; hypertension; hyperlipidemia; renal, hepatic, and vascular diseases; malignancies; anemia; hypothyroidism; intake of methotrexate, phenytoin, carbamazepine, NO, theophyline, metformin, colestipol, niacin, penicillamine, thiazide diuretics, vitamin B6, cobalamin, and/or folate supplements; excessive coffee consumption; chronic alcohol intake; and current smoking were excluded. Strenuous physical activity was not allowed before collection of blood samples. All participants were informed about the study and gave their written consent. The study was approved by the ethics committee of Gulhane Military Medical Academy.

Therapy and analysis

Patients with IHH were treated with a single dose im injection of Sustanon 250 (Organon, Oss, The Netherlands) that contained 30 mg T propionate, 60 mg T phenylpropionate, 60 mg T isocaproate, and 100 mg T decanoate.

Fasting blood samples were collected from patients and controls between 0800–0830 h after overnight fasting. Posttreatment blood samples were drawn 10 d after the injection of Sustanon. Blood samples were put on ice. Venous blood samples were centrifuged within less than 60 min. The plasma and serum was stored at –80 C until tHcy, ADMA, L-arginine, and NOx levels could be measured.

Measurement of L-arginine and ADMA was accomplished by HPLC, using the method described by Chen et al. (25). In brief, to 1 ml serum, 20 mg 5-sulfosalisilic acid was added, and the mixture was left in an ice bath for 10 min. The precipitated protein was removed by centrifugation at 2000 x g for 10 min. Ten microliters of the supernatant which was filtered through a 0.2-µm pore size filter was mixed with 100 µl derivatization reagent (prepared by dissolving 10 mg o-phtaldialdehyde in 0.5 ml methanol, 2 ml 0.4 M borate buffer (pH 10.0), and 30 µl 2-mercaptoethanol were added) and then injected into the chromatographic system. Separation of L-arginine and ADMA was achieved with a 150 x 4-mm interior diameter Nova-Pak C18 column with a particle size of 5 µm (Waters, Millipore Corp., Milford, MA) using 50 mM sodium acetate (pH 6.8), methanol, and tetrahydrofurane as mobile phase (A, 82:17:1; B, 22:77:1) at a flow rate of 1.0 ml/min. The areas of peaks detected by fluorescent detector (excitation, 338 nm; emission, 425 nm) were used for quantification. The variability of the method was less than 7%, and the detection limit of the assay was 0.1 µM.

Plasma NOx levels were measured in triplicate after conversion of nitrate to nitrite by nitrate reductase, and nitrite was measured using the Griess reaction as described previously (26) The intra- and interassay coefficients of variation were 3% and 7%, respectively. Recoveries of both nitrites and nitrates in our samples were greater than 95%.

Total plasma cholesterol and triglyceride levels were measured by enzymatic colorimetric method with an Olympus AU 2700 autoanalyzer using reagents from Olympus Diagnostics, GmbH (Hamburg, Germany). Serum creatinine levels were determined using a modified kinetic Jaffe method.

Plasma tHcy concentrations were measured by HPLC (HP Agilent 1100, Agilent Technologies, Palo Alto, CA) (27). Cobalamin and folate levels were measured by RIA with reagents from Diagnostic Product Corp. (Los Angeles, CA). Serum FSH, LH, estradiol (E2), and prolactin concentrations were measured by immunoradiometric assay with reagents from Radim Techland (Angleur, Belgium). Serum total T concentrations were determined by a solid phase 125I RIA with reagents from Diagnostic Product Corp. The free T values were obtained by calculation from T and SHBG values according to the method proposed by Vermeulen et al. (28). Serum total T was determined by RIA with reagents from Diagnostic Systems Laboratories, Inc. (Webster, TX; active testosterone kit). The intra- and interassay coefficients of variation for total T were 8.7% and 10.5%. Serum SHBG levels were measured by RIA with a reagent from Radim Techland. The normal ranges in our laboratory are less than 15 IU/liter for FSH, less than 20 IU/liter for LH, less than 60 pg/ml for E2, 15–45 pg/ml for free T, and 9–38 nmol/liter for SHBG.

Statistical analyses

All of the statistical analyses were performed using the SPSS 11.0 (SPSSFW, SPSS, Inc., Chicago, IL) statistical package. Descriptive statistics were given as the arithmetic mean ± SD. For the pairwise comparisons, we used a paired sample t test when the normality assumptions were held, and Wilcoxon signed rank test otherwise. For comparisons of the values of two different groups, we used an independent sample t test. P ≤ 0.05 was considered statistically significant.


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Pretreatment and posttreatment clinical and laboratory characteristics and the results of comparisons are given in Table 1Go. Pretreatment levels of FSH, LH, E2, and free T were lower in patients than in controls; posttreatment levels of free T were statistically significantly increased, and FSH, LH, and E2 levels were not changed. SHBG was higher than control levels before therapy, whereas it did not change after treatment. Prolactin levels did not differ significantly between groups.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Laboratory parameters of patient and control groups

 
Compared with controls, pre- and posttreatment levels of creatinine were significantly lower. There was no difference between patients and controls with respect to the mean levels of total cholesterol and triglycerides.

The pretreatment folate and cobalamin levels were statistically significantly higher in patients compared with controls, and they did not change significantly after treatment. The IHH patients had lower tHcy levels than controls. Plasma fasting tHcy concentrations was not statistically significant after 10 d of treatment.

The pretreatment ADMA and L-arginine levels were significantly higher, and NOx levels were lower than those in the control group. After 10 d of treatment, ADMA and L-arginine levels were significantly reduced, and NOx levels were significantly increased. There was a significant positive correlation (P < 0.01) between ADMA and L-arginine, and a negative correlation between ADMA and NOx levels in patients and controls. There is not a significant, direct relationship between free T levels and plasma ADMA or between free T levels and NOx.

IHH patients exhibited a significant increase in L-arginine compared with both control and posttreatment groups (P < 0.01), whereas L-arginine remained unaltered in the posttreatment group compared with the controls. The pretreatment group also revealed a significant increase in ADMA plasma levels (P < 0.01).


    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
The main findings of our study are that 1) L-arginine and ADMA levels are increased, whereas NOx levels are decreased in plasma from IHH patients; 2) the posttreatment group does not reveal any difference in L-arginine, ADMA, or NOx concentrations compared with the control group.

The finding of elevated ADMA levels in patients with IHH that are returned to the control group values after acute T treatment shows a possible relationship between T and ADMA metabolism. However, the mechanisms involved in the rise in ADMA concentrations in the present study have not been defined. Plasma dimethylarginines arise mainly from degradation of intracellular methylated proteins and are eliminated via urinary excretion (29) ADMA is also metabolized by the intracellular enzyme dimethylarginine dimethylaminohydrolase (30). At least three possibilities exist for an elevation of plasma ADMA: a decrease in renal filtration, an increased synthesis of ADMA, and a decreased enzymatic hydrolysis. Elevated ADMA, attributable to reduced renal excretion, is unlikely, because creatinine plasma levels in the groups were within normal values.

Several lines of evidence indicate that ADMA is synthesized from the degradation of methylated proteins rather than from the methylation of free arginine. The specific enzyme protein arginine N-methyltransferase (protein methylase I) has been shown to methylate internal arginine residues in a variety of polypeptides. Catabolism of these polypeptides generates ADMA and NG,NG’-dimethyl-L-arginine (29, 31). It could be hypothesized that T would down-regulate protein methylase I activity or decrease dimethylarginine dimethylaminohydrolase activity, offering a putative mechanism for elevated ADMA levels associated with hypogonadism. Moreover, in a recent study elevation of T levels in hypogonadal men, whether endogenously by Leydig cell stimulation or exogenously by injection of T, caused endothelium-dependent vasoreactivity to decrease into the range found in eugonadal men (32).

The clinical relevance of these findings has to be judged from the general perspective of other known effects of T on cardiovascular risk factors. In men, the influence of androgens on body composition and insulin resistance and the modulation of factors involved in clotting and fibrinolysis have to be considered beneficial. The decreasing effect of androgen substitution on high density lipoprotein cholesterol has, at least theoretically (8), to be regarded as adverse, although clinical evidence is lacking. As demonstrated in this trial, elevated ADMA levels lowered by parenteral T administration in hypogonadal men may contribute to the diminished endothelial function that was previously reported (32).

Gyurko et al. (33) have shown that NO generated by neuronal NOS is necessary for normal reproductive function in the mouse. Furthermore, in the male, NO is required for normal mating behavior, FSH secretion, and testicular development. Because NOS is also expressed in the gonads, we considered the possibility that ADMA may cause local NOS inhibition that is responsible for the infertility.

We have also shown that the plasma fasting tHcy concentrations in patients with IHH were lower in pre- and posttreatment groups than in the control group. Short-term T therapy had no effect on plasma tHcy levels. However, it was previously reported that long-term T treatment increases tHcy values (34).

In conclusion, these data show that an elevation of plasma ADMA levels in patients with IHH associated with a reduction in NO production may contribute to some cardiovascular alterations. Single dose parenteral T administration lowered ADMA concentrations and increased NO production to the control group values. Additional studies will be required to understand the mechanisms responsible for the observed effects and their consequences.


    Footnotes
 
First Published Online December 21, 2004

Abbreviations: ADMA, Asymmetric NG,NG-dimethyl-L-arginine; E2, estradiol; IHH, idiopathic hypogonadotropic hypogonadism; NO, nitric oxide; NOx, plasma nitrite plus nitrate; T, testosterone; tHcy, total homocysteine.

Received October 15, 2004.

Accepted December 13, 2004.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Advisory Panel on Testosterone Replacement in Men 2001 Report of National Institute on Aging Advisory Panel on Testosterone Replacement in Men. J Clin Endocrinol Metab 86:4611–4614[Free Full Text]
  2. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E 1997 Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom study. J Clin Endocrinol Metab 82:682–685[Abstract/Free Full Text]
  3. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL 2002 Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 25:55–60[Abstract/Free Full Text]
  4. Winkler UH 1996 Effects of androgens on hemostasis. Maturitas 24:147–155[Medline]
  5. Zitzmann M, Junker R, Kamischke A, Nieschlag E 2002 Contraceptive steroids influence the hemostatic activation state in healthy males. J Androl 23:503–511[Abstract/Free Full Text]
  6. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS 2001 Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 111:261–269[CrossRef][Medline]
  7. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136–143[Abstract/Free Full Text]
  8. Assmann G, Schulte H, von Eckardstein A, Huang Y 1996 High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124:S11–S12
  9. Oktenli C, Yesilova Z, Ozata M, Yaman H, Tuzun A, Dundar S, Sanisoglu SY, Musabak U, Erbil MK, Dagalp K 2003 Gonadotropin treatment increases homocysteine levels in idiopathic hypogonadotropic hypogonadism: an indirect effect mediated by changes in body composition. J Endocrinol 179:35–39[Abstract]
  10. Adams MR, Williams JK, Kaplan JR 1995 Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15:562–570[Abstract/Free Full Text]
  11. Drexler H, Hornig B 1999 Endothelial dysfunction in human disease. J Mol Cell Cardiol 31:51–60[CrossRef][Medline]
  12. Esper RJ, Vilarino J, Cacharron JL, Machado R, Ingino CA, Garcia Guinazu CA, Bereziuk E, Bolano AL, Suarez DH, Kura M 1999 Impaired endothelial function in patients with rapidly stabilized unstable angina: assessment by noninvasive brachial artery ultrasonography. Clin Cardiol 22:699–703[Medline]
  13. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC 1995 Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26:1235–1241[Abstract]
  14. Sader MA, Celermajer DS 2002 Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 15:597–604
  15. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, Chatterjee K 1996 Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 94:2614–2619[Abstract/Free Full Text]
  16. Molinari C, Battaglia A, Grossini E, Mary DA, Vassanelli C, Vacca G 2002 The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 543:365–372[Abstract/Free Full Text]
  17. Ignarro LJ, Byrns RE, Buga GM, Wood KS 1987 Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacological and chemical properties that are identical to those of nitric oxide radical. Circ Res 61:866–879[Abstract/Free Full Text]
  18. Palmer RMJ, Ferrige AG, Moncada S 1987 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524–526[CrossRef][Medline]
  19. Moncada S, Higgs A 1993 The L-arginine-nitric oxide pathway. N Engl J Med 329:2002–2012[Free Full Text]
  20. Lowenstein CJ, Dinerman JL, Snyder SH 1994 Nitric oxide: a physiologic messenger. Ann Intern Med 120:227–237[Abstract/Free Full Text]
  21. Vallance P, Leone A, Calver A, Collier J, Moncada S 1992 Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572–575[CrossRef][Medline]
  22. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC 1999 Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594–600[Abstract/Free Full Text]
  23. Leiper JF, Vallance P 1999 Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43:542–548[Abstract/Free Full Text]
  24. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K 2000 Study on the relationship between plasma nitrite and nitrate level and salt sensitive in human hypertension. Circulation 101:856–861[Abstract/Free Full Text]
  25. Chen BM, Xia LW, Zhao RQ 1997 Determination of NG ,NG–dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B 2:467–471
  26. Moshage H, Kok B, Huizenga JR, Jansen PL 1995 Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41:892–896[Abstract/Free Full Text]
  27. Araki A, Sako Y 1987 Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43–52[Medline]
  28. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672[Abstract/Free Full Text]
  29. McDermott JR 1976 Studies on the catabolism of Ng-methylarginine, Ng,Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 15:179–184
  30. Ogawa T, Kimoto M, Sasaoka K 1989 Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264:10205–10209[Abstract/Free Full Text]
  31. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P 1996 Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119:1533–154[Medline]
  32. Zitzmann M, Brune M, Nieschlag E 2002 Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 87:5030–5037[Abstract/Free Full Text]
  33. Gyurko R, Leupen S, Huang PL 2002 Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology 143:2767–2774[Abstract/Free Full Text]
  34. Yesilova Z, Ozata M, Oktenli C, Sanisoglu SY, Erbil MK, Dagalp K 2004 Effect of supraphysiologic doses of testosterone on fasting plasma total homocysteine concentrations in men with Klinefelter’s syndrome. Fertil Steril 81:1278–1282[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/3/1651    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cakir, E.
Right arrow Articles by Yesilova, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cakir, E.
Right arrow Articles by Yesilova, Z.
Related Collections
Right arrow Male Endocrinology


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals